LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia

COVID-19 Clinical Trial

Official title:

A Phase 2 Study to Evaluate LB1148 for the Treatment of Pulmonary Dysfunction Associated With COVID-19 Pneumonia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04390217
• Other study ID #: LBS-COVID19-201
• Status: Withdrawn
• Phase: Phase 2
• Start date: October 31, 2021
• Est. completion date: March 31, 2022

Study information

• Verified date: May 2022
• Source: Palisade Bio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 2, proof of concept, randomized, placebo-controlled, multicenter study to evaluate the ability of LB1148 to attenuate pulmonary dysfunction associated with COVID-19 pneumonia. The primary objective of this study is to determine if enteral administration of LB1148 will effect disease progression in hospitalized patients with moderate to severe COVID-19 via measurement of the proportion of subjects alive and free of respiratory failure at Day 28.

Description:

The purpose of this study is to establish the safety and tolerability, along with preliminary evidence of efficacy, of LB1148 compared to placebo in hospitalized patients with moderate to severe coronavirus disease (COVID-19). All patients will be randomized into one of two treatment groups (LB1148 or Placebo) in a 1:1 ratio, and stratified by peripheral capillary oxygen saturation (SpO2) ≥ 93% on room air vs. < 93% on room air, and by PF ratio (PaO2, arterial oxygen partial pressure, to FiO2, fractional inspired oxygen) of ≥ 300 mmHg vs. PF ratio of < 300 mmHg at the time of Screening. (If PaO2 cannot be measured or acquired, SpO2 may be substituted to calculate the PF ratio.) LB1148 contains 7.5 g tranexamic acid (TXA), polyethylene glycol (PEG), glucose, and electrolytes. A total of 700 mL of LB1148 will be administered enterally, as a split dose (350 mL, every 12 hours). Study drug is given as a single bolus, to be delivered orally or via nasogastric (NG) or orogastric (OG) tube. For those patients assigned to placebo, a total of 700 mL of placebo will be administered enterally, as a split dose (350 mL, every 12 hours). The placebo contains PEG, glucose, and electrolytes.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 31, 2022
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult patients (18 years of age or older) with the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, confirmed via an established standard reverse transcriptase polymerase chain reaction (RT-PCR) assay.

2. Patient or patient's legally authorized representative is willing and able to provide informed consent prior to performing any study-related procedures.

3. Patient is hospitalized and requires some form of supplemental oxygen, e.g., non-invasive ventilation, high flow oxygen device, or oxygen by mask or nasal cannula.

4. Patient has radiographic evidence of pulmonary infiltrate(s) or lung inflammation.

Exclusion Criteria:

1. Participation in any other interventional clinical trial using an experimental treatment (drug or device) for COVID-19.

2. Expected survival or time to withdrawal of life-sustaining treatments is expected to be < 7 days.

3. Patients with do not intubate orders.

4. Patients who require invasive mechanical ventilation at the time of Screening.

5. Patients who require renal replacement therapy (RRT) at the time of Screening.

6. Patients with known aspiration problems.

7. Has contraindications or potential risk factors to taking TXA. These include patients

with:

1. Known sensitivity to TXA;

2. Recent craniotomy (past 30 days);

3. Active cerebrovascular bleed;

4. Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome);

5. Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction

6. Continuing use of a combined hormonal contraceptive and or combined hormonal replacement therapy (including combined hormonal pill, patch, or vaginal ring).

7. Concomitant therapy with tissue plasminogen activators, Factor IX complex concentrates or anti-inhibitor coagulant concentrates.

8. Known medical history of congenital or acquired thrombophilia such as, but not limited

to patients with:

1. Sickle cell disease

2. Nephrotic syndrome

3. Factor V Leiden

4. Prothrombin gene mutation

5. Protein C or S deficiency

6. Antithrombin III deficiency

7. Antiphospholipid syndrome

9. Patients with myeloproliferative disorders.

10. Any other condition that, in the opinion of the treating Investigator, would preclude the patient from being an appropriate candidate for the study.

11. Female patients who are pregnant or breastfeeding at the time of Screening.

Related Conditions & MeSH terms

• Coronavirus Disease 2019
• COVID-19
• COVID-19 Pneumonia
• Covid19
• Pneumonia

Intervention

Drug:
• LB1148
LB1148 is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.
• Placebo
Placebo is delivered orally/enterally, 700 mL per day split into two administrations of 350 mL, approximately 12 hours apart, for up to 7 days.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Leading BioSciences, Inc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effect of LB1148 on disease progression via measurement of the proportion of patients who are alive and free of respiratory failure.	The proportion of subjects alive and free of respiratory failure at Day 28.	28 Days
Secondary	Clinical status at fixed time points	Number and proportion of patients with improved clinical status as assessed by a 9-point ordinal scale of disease severity at fixed timepoints (Days 3, 5, 7, 8, 10, 14, 28)	Measured at 3, 5, 7, 8, 10, 14 and 28 Days
Secondary	Duration of hospital stay	Length of hospital stay (live discharge)	28 Days
Secondary	Measurement of the number and proportion of patients requiring admission to the intensive care unit (ICU) during hospitalization	Number and proportion of patients requiring admission to the intensive care unit	28 Days
Secondary	Duration of ICU stay	Length of ICU stay	28 Days
Secondary	Invasive mechanical ventilation requirements	Number and proportion of patients requiring invasive mechanical ventilation	28 Days
Secondary	Duration of invasive mechanical ventilation	Length of time patients require invasive mechanical ventilation	28 Days
Secondary	All-cause 28-day mortality	The number and proportion of patients deceased at Day 28	28 Days
Secondary	Safety and tolerability of LB1148	The incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)	28 Days